{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=vehicle&page=2",
    "query": {
      "intervention": "vehicle",
      "page": 2
    },
    "page_size": 10
  },
  "pagination": {
    "page": 2,
    "page_size": 10,
    "total_count": 10,
    "total_pages": 1,
    "next_page_url": null,
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=vehicle&page=1&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-09-25T11:46:27.422Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT03602612",
      "title": "T Cells Expressing a Novel Fully-Human Anti-BCMA CAR for Treating Multiple Myeloma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Myeloma-Multiple",
        "Myeloma, Plasma-Cell"
      ],
      "interventions": [
        {
          "name": "Cyclophosphamide",
          "type": "DRUG"
        },
        {
          "name": "Fludarabine",
          "type": "DRUG"
        },
        {
          "name": "Anti-B Cell Maturation Antigen (BCMA) chimeric antigen receptors (CARs) T cells",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "73 Years",
        "sex": "ALL",
        "summary": "18 Years to 73 Years"
      },
      "enrollment_count": 35,
      "start_date": "2018-09-14",
      "completion_date": "2026-04-23",
      "has_results": true,
      "last_update_posted_date": "2026-06-16",
      "last_synced_at": "2026-09-25T11:46:27.422Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03602612"
    },
    {
      "nct_id": "NCT02682407",
      "title": "Safety Study of IgAN, LN, MN, & C3 Glomerulopathy Including Dense Deposit Disease Treated With OMS721",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "IgAN",
        "LN",
        "MN",
        "C3G"
      ],
      "interventions": [
        {
          "name": "OMS721 (narsoplimab)",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Omeros Corporation",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 31,
      "start_date": "2016-03-10",
      "completion_date": "2020-08-25",
      "has_results": true,
      "last_update_posted_date": "2026-03-30",
      "last_synced_at": "2026-09-25T11:46:27.422Z",
      "location_count": 8,
      "location_summary": "Denver, Colorado • Augusta, Georgia • Lawrenceville, Georgia + 5 more",
      "locations": [
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Augusta",
          "state": "Georgia"
        },
        {
          "city": "Lawrenceville",
          "state": "Georgia"
        },
        {
          "city": "Evergreen Park",
          "state": "Illinois"
        },
        {
          "city": "Voorhees Township",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02682407"
    },
    {
      "nct_id": "NCT07599800",
      "title": "A Phase IIb/III Clinical Study to Evaluate the Efficacy and Safety of APC101 in Patients With Postherpetic Neuralgia.",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2",
        "PHASE3"
      ],
      "conditions": [
        "PHN - Post-Herpetic Neuritis"
      ],
      "interventions": [
        {
          "name": "APC101",
          "type": "DRUG"
        },
        {
          "name": "Control",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Andros Pharmaceuticals Co., Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 333,
      "start_date": "2026-08-01",
      "completion_date": "2029-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-05-20",
      "last_synced_at": "2026-09-25T11:46:27.422Z",
      "location_count": 1,
      "location_summary": "Florida City, Florida",
      "locations": [
        {
          "city": "Florida City",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07599800"
    },
    {
      "nct_id": "NCT03233737",
      "title": "Pain Study to Assess Local Anesthetic Efficacy and Safety of CTY-5339 on Gingival Mucosal Tissue in Normal Volunteers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "No Disease State or Condition"
      ],
      "interventions": [
        {
          "name": "One spray CTY-5339-A",
          "type": "COMBINATION_PRODUCT"
        },
        {
          "name": "One spray CTY-5339-CB",
          "type": "DEVICE"
        },
        {
          "name": "One spray CTY-5339-P",
          "type": "DEVICE"
        }
      ],
      "intervention_types": [
        "COMBINATION_PRODUCT",
        "DEVICE"
      ],
      "sponsor": "Cetylite Industries",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 75,
      "start_date": "2017-06-15",
      "completion_date": "2018-02-20",
      "has_results": true,
      "last_update_posted_date": "2019-08-21",
      "last_synced_at": "2026-09-25T11:46:27.422Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03233737"
    },
    {
      "nct_id": "NCT06369675",
      "title": "Skin Irritation Potential of MOB015B in Healthy Subjects Using a Cumulative Irritant Patch Test Design",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Erythema"
      ],
      "interventions": [
        {
          "name": "MOB015B",
          "type": "DRUG"
        },
        {
          "name": "0.2% SLS",
          "type": "DRUG"
        },
        {
          "name": "0.9% Saline",
          "type": "DRUG"
        },
        {
          "name": "MOB015B vehicle",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Moberg Pharma AB",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 45,
      "start_date": "2017-10-19",
      "completion_date": "2017-11-14",
      "has_results": false,
      "last_update_posted_date": "2024-04-17",
      "last_synced_at": "2026-09-25T11:46:27.422Z",
      "location_count": 1,
      "location_summary": "Fair Lawn, New Jersey",
      "locations": [
        {
          "city": "Fair Lawn",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06369675"
    },
    {
      "nct_id": "NCT03181009",
      "title": "Multi OIT to Test Immune Markers After Minimum Maintenance Dose",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Food Allergy"
      ],
      "interventions": [
        {
          "name": "Omalizumab",
          "type": "DRUG"
        },
        {
          "name": "Food Flour Allergens",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Andrew Long, PharmD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "2 Years",
        "maximum_age": "25 Years",
        "sex": "ALL",
        "summary": "2 Years to 25 Years"
      },
      "enrollment_count": 60,
      "start_date": "2017-07-31",
      "completion_date": "2019-01-30",
      "has_results": true,
      "last_update_posted_date": "2026-04-27",
      "last_synced_at": "2026-09-25T11:46:27.422Z",
      "location_count": 2,
      "location_summary": "Los Angeles, California • Mountain View, California",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Mountain View",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03181009"
    },
    {
      "nct_id": "NCT05109702",
      "title": "A Study to Assess the Efficacy and Safety of Tanfanercept (HL036) Ophthalmic Solution in Participants With Dry Eye",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Dry Eye"
      ],
      "interventions": [
        {
          "name": "0.25% Tanfanercept Ophthalmic Solution",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "HanAll BioPharma Co., Ltd.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 260,
      "start_date": "2021-11-18",
      "completion_date": "2022-05-06",
      "has_results": true,
      "last_update_posted_date": "2023-10-23",
      "last_synced_at": "2026-09-25T11:46:27.422Z",
      "location_count": 10,
      "location_summary": "Phoenix, Arizona • Glendale, California • Newport Beach, California + 7 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Glendale",
          "state": "California"
        },
        {
          "city": "Newport Beach",
          "state": "California"
        },
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "Raynham",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05109702"
    },
    {
      "nct_id": "NCT00402701",
      "title": "Pedestrian Behavior Following Implementation of a Walking School Bus",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Obesity"
      ],
      "interventions": [
        {
          "name": "Walking School Bus Program",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "University of Washington",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "5 Years",
        "maximum_age": "12 Years",
        "sex": "ALL",
        "summary": "5 Years to 12 Years"
      },
      "enrollment_count": 735,
      "start_date": "2004-11",
      "completion_date": "2006-04",
      "has_results": false,
      "last_update_posted_date": "2024-05-09",
      "last_synced_at": "2026-09-25T11:46:27.422Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00402701"
    },
    {
      "nct_id": "NCT02634853",
      "title": "A Safety and Efficacy Study of Tavilermide (MIM-D3) Ophthalmic Solution for the Treatment of Dry Eye",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Keratoconjunctivitis Sicca"
      ],
      "interventions": [
        {
          "name": "1% Tavilermide Ophthalmic Solution",
          "type": "DRUG"
        },
        {
          "name": "Placebo Ophthalmic Solution",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mimetogen Pharmaceuticals USA, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 429,
      "start_date": "2015-12",
      "completion_date": "2017-03",
      "has_results": false,
      "last_update_posted_date": "2019-08-16",
      "last_synced_at": "2026-09-25T11:46:27.422Z",
      "location_count": 2,
      "location_summary": "Louisville, Kentucky • Nashville, Tennessee",
      "locations": [
        {
          "city": "Louisville",
          "state": "Kentucky"
        },
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02634853"
    },
    {
      "nct_id": "NCT03278028",
      "title": "A Study of A-101 Topical Solution Administered Twice a Week in Subjects With Common Warts",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Common Wart"
      ],
      "interventions": [
        {
          "name": "A-101 Topical Solution",
          "type": "DRUG"
        },
        {
          "name": "A-101 Vehicle Solution",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Aclaris Therapeutics, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "8 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "8 Years and older"
      },
      "enrollment_count": 159,
      "start_date": "2017-07-13",
      "completion_date": "2018-03-01",
      "has_results": true,
      "last_update_posted_date": "2019-04-09",
      "last_synced_at": "2026-09-25T11:46:27.422Z",
      "location_count": 16,
      "location_summary": "Glendale, Arizona • Fort Smith, Arkansas • Encinitas, California + 13 more",
      "locations": [
        {
          "city": "Glendale",
          "state": "Arizona"
        },
        {
          "city": "Fort Smith",
          "state": "Arkansas"
        },
        {
          "city": "Encinitas",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03278028"
    }
  ]
}